Optimizing the Posthospital Period After Admission for Worsening Heart Failure.

Competing Interests: Funding Support and Author Disclosures Dr Rosano has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, Medtronic, and Vifor; and has received grants from Bayer, Cytokinetics, Menarini, and Servier, outside of the submitted work. Dr Savarese has received grants and personal fees from Vifor, Boehringer Ingelheim, AstraZeneca, Novartis, Cytokinetics, and Pharmacosmos; personal fees from Servier, Medtronic, TEVA, Abbott, Edwards Lifesciences, INTAS, and Abbott; and grants from Boston Scientific, Merck, and Bayer, outside of the submitted work. Dr Böhm is supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) (TTR 219, project number 322900939); and has received personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor, Servier, and Vifor. Dr Teerlink has received research contracts and/or consulting fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardiol, Cardurion, Chugai, Cytokinetics, Daiichi Sankyo, EBR Systems, Edwards Lifesciences, Elsevier, FibroGen, GlaxoSmithKline, Guidepoint Global, Kaiser Permanente, Lilly, LivaNova, Medtronic, Novartis, Occlutech, ReCor Medical, Regeneron, scPharma, Verily, VoxMedia, V Wave, and Windtree Therapeutics.